{"prompt": "['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 6 of 61', 'Medtronic', '13.1.9', 'Patient Populations', '44', '13.2 Primary Objective', '45', '13.3 Secondary Objective', '46', '13.4 Additional Measures', '46', '14. Ethics', '47', '14.1.', 'Statement(s) of Compliance', '47', '14.2.', 'Principal Investigator Oversight', '48', '15. Study Administration', '53', '15.1.', 'Sponsor', '53', '15.2.', 'Site Selection', '53', '15.3.', 'Clinical Trial Agreement', '53', '15.4.', 'Curriculum Vitae', '53', '15.5.', 'Monitoring', '53', '15.6.', 'Medtronic Representative Role', '54', '15.7.', 'Data Management', '54', '15.8.', 'Direct Access to Source Data/Documents', '55', '15.9.', 'Confidentiality', '55', '15.10.', 'Liability', '56', '15.11.', 'CIP Amendments', '56', '15.12.', 'Record Retention', '56', '15.13. Publication and Use of Information', '57', '15.14.', 'Suspension or Early Termination', '57', '16. References', '59', '17. Appendices', '60', '17.1.', 'Appendix A: Additional Information for Sites', '60', '17.2.', 'Appendix B: Institutional Review Boards/Ethics Committees', '60', '17.3.', 'Appendix C: Participating Investigators and Institutions', '60', '17.4.', 'Appendix D: Informed Consent Materials', '60', '18. Version History', '61', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 7 of 61', 'Medtronic', '2. Glossary', 'TERM', 'DEFINITION', 'ADE', 'Adverse Device Effect', 'ADVANCED EVALUATION', 'Therapy evaluation using InterStim Tined Lead', 'AE', 'Adverse Event', 'AT', 'As Treated', 'AWC', 'Adjusted Worst Case', 'BASIC EVALUATION', 'Therapy evaluation using temporary Test Stimulation Lead', 'CC', 'Complete Case', 'CFR', 'Code of Federal Regulations', 'CIP', 'Clinical Investigational Plan', 'eCRF', 'Electronic Case Report Form', 'FAS', 'Full Analysis Set', 'FDA', 'Food and Drug Administration', 'GCP', 'Good Clinical Practice', 'HIPAA', 'Health Insurance Portability and Accountability Act', 'ICF', 'Informed Consent Form', 'IDE', 'Investigational Device Exemption', 'IRB', 'Institutional Review Board', 'LOCF', 'Last Observation Carried Forward', 'NPU', 'Neuro Programmer Upload', 'OAB', 'Overactive Bladder', 'ICIQ-OABqol', 'International Consultation on Incontinence Modular', 'Questionnaire - Overactive Bladder Symptoms Quality of Life', 'Questionnaire', 'PNE', 'Peripheral Nerve Evaluation', 'QoL', 'Quality of Life', 'ORACLE RDC', 'Oracle Remote Data Capture', 'REPORTABLE ADVERSE EVENTS AND', 'Serious, device-related, procedure-related, therapy-related', 'DEVICE DEFICIENCIES', 'adverse events and all device deficiencies will be considered', 'reportable for this study', 'SADE', 'Serious Adverse Device Effect', 'SAE', 'Serious Adverse Events', 'SAP', 'Statistical Analysis Plan', 'SENSORY THRESHOLD', 'Sensory threshold is defined as the lowest amplitude where', 'the subject first perceives sensation of the stimulation in the', 'perineum, perianal, vaginal, or any location deemed', 'appropriate by the investigator while in a seated position.', 'SNM', 'Sacral Neuromodulation', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 8 of 61', 'Medtronic', 'TERM', 'DEFINITION', 'USADE', 'Unanticipated Serious Adverse Device Effect', 'UF', 'Urgency Frequency', 'UI', 'Urinary Incontinence', 'UUI', 'Urinary Urge Incontinence', 'US', 'United States', 'UTI', 'Urinary Tract Infection', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']\n\n###\n\n", "completion": "END"}